AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T Cell Therapies
Shots:
- Caribou to receive $40M up front in cash & equity investment- ~$300M in development- regulatory- and launch milestones along with additional commercial milestones and global royalties
- AbbVie will utilize and gets exclusive rights to Caribou's next-generation Cas12a chRDNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to specified targets
- Caribou will responsible for pre-clinical research- development- and manufacturing activities for the collaboration programs and AbbVie will reimburse Caribou for all such activities pursuant to the deal
Ref: Abbvie | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
